A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination with Cemiplimab-rwlc (Libtayo ) in Subjects with Recurrent or Progressive Glioblastoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Recurrent Or Progressive Glioblastoma
  • Age: Between 18 - 75 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Provision of written informed consent for tumor biopsy or tumor resection, tissue and blood sample collection, and treatment with investigational products prior to undergoing any study-specific procedures. 2) Histologically confirmed glioblastoma from archival tissue. 3) Evidence of tumor recurrence/progression by magnetic resonance imaging (MRI) according to Response Assessment in Neuro-Oncology (RANO) criteria after at least standard initial therapy. 4) Previous standard-of-care treatment must include surgery and/or biopsy and chemoradiation.

You may not be eligible for this study if the following are true:

  • 1) Radiotherapy treatment within 4 weeks of starting veledimex. 2) Prior treatment of disease with bevacizumab. 3) Uncontrolled infection with human immunodeficiency virus, hepatitis B or hepatitis C infection; or diagnosis of immunodeficiency.

If you are registered as a volunteer, please login to the dashboard to send referrals.